Octreotide vs Pramlintide
Overview
Octreotide is primarily a hormonal peptide, while Pramlintide is used for weight management & metabolic.
This page compares Octreotide and Pramlintide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Octreotide | Pramlintide | |
|---|---|---|
| Category | Hormonal | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) | 60-120 mcg |
| Frequency | Every 4 weeks (LAR); two to four times daily (immediate-release) | with meals |
| Reported benefits | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers | Reduced post-meal glucose, weight loss, appetite control |
| Reported side effects | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain | Nausea, hypoglycemia risk with insulin |
Key differences
Primary use. Octreotide is categorised under Hormonal, while Pramlintide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Octreotide: FDA-approved. Pramlintide: FDA-approved.
Dosing. Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)). Pramlintide is typically dosed at 60-120 mcg (with meals).
Can you stack them?
Some protocols combine peptides, but stacking Octreotide and Pramlintide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Octreotide and Pramlintide?
- Octreotide is primarily a hormonal peptide, while Pramlintide is used for weight management & metabolic. Octreotide is FDA-approved for one or more indications, whereas Pramlintide is FDA-approved for one or more indications.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- What is Pramlintide used for?
- Amylin analog for diabetes.
- Can you take Octreotide and Pramlintide together?
- Some users combine peptides within a single protocol, but stacking Octreotide and Pramlintide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Octreotide or Pramlintide FDA-approved?
- Octreotide is FDA-approved for one or more indications. Pramlintide is FDA-approved for one or more indications.
Read the full articles
- Octreotide — full monograph: mechanism, research, dosing & references
- Pramlintide — full monograph: mechanism, research, dosing & references